Ascend Plastic Surgery Partners recently announced a partnership with Ponte Vedra Plastic Surgery (PVPS).
According to Ascend, the partnership advances its mission to elevate patient care standards and provide exemplary aesthetic services across the United States. PVPS expands Ascend’s presence into Florida, adding a fifth state, six additional surgeons, and six new locations to the Ascend footprint.
PVPS was founded 30 years ago. Founding partners Dr. Cayce Rumsey and Dr. Robert Burk partnered with Dr. Erez Sternberg, Dr. Hollie Hickman and CEO Dennis Oistacher to cultivate an operation focused on advancing aesthetic medicine and embodying a culture of excellence.
“Joining forces with Ascend Plastic Surgery Partners represents a pivotal chapter in our journey,” said Oistacher. “It’s a partnership that reflects our shared commitment to unparalleled patient care, innovation, and the continuation of the legacy we’ve built at PVPS.”
Ascend, under the leadership of Chief Medical Officer Dr. William Hedden and CEO Anthony Milonas, is recognized for its commitment to clinical excellence and personalized patient experiences.
“The integration of PVPS into the Ascend family marks a momentous step forward in our quest to set a new standard of excellence in the aesthetic medicine industry,” Milonas said. “We are honored to carry forward the incredible legacy of PVPS, a testament to the vision of its founders and the dedication of its team.”
“We are excited for the next phase of PVPS’s growth and are thrilled to partner with the Ascend team,” said Burk. “We are looking forward to sharing in best practices while continuing to optimize patient care and results, as we look to expand.”
The focus remains on preserving the strong company culture and positive attributes that have defined PVPS. This merger not only signifies a blending of talents and resources but also a shared vision for the future of aesthetic medicine, where patient well-being and clinical excellence lead the way.
PVPS was advised by Westcove Partners and Advos Legal. Ascend was advised by McDermott Will & Emery and Berkley Research Group.
